The non-invasive deep brain stimulation device operates through electrodes placed on the cranium. Credit: Gorodenkoff/Shutterstock.com.

Nexalin Technology has secured a US patent related to its non-invasive, frequency-based deep brain stimulation device, Gen-3 HALO Clarity system.

Awarded by the United States Patent and Trademark Office (USPTO), the patent is entitled “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia (ADI)”.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It covers the method of use for the device, which is designed to treat anxiety, depression, and insomnia (ADI), from the comfort of patients’ homes.

Nexalin Technology CEO Mark White said: “This method of use patent award marks a major achievement for the company and follows another recent patent covering our core technology.

“These patents extend through 2040 and are a critical element of our overall strategy, given the mounting clinical data supporting the benefits of our noninvasive, deep frequency brain stimulation technology in the fields of insomnia, depression, and anxiety.”

See Also:

The Gen-3 HALO Clarity, which represents a significant advancement over the previous Gen-1 system, features Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Using a digital breakthrough in electrical waveforms, the DIFS technology provides deep brain neural stimulation.

The non-invasive deep brain stimulation device operates through electrodes placed on the cranium, targeting brain regions associated with mental health.

White added: “A key differentiator for our new Gen-3 HALO Clarity is that, for the first time, it enables patients to receive this treatment in the privacy of their own homes with remote monitoring by a physician in Nexalin’s Virtual Clinic.

“Importantly, we are advancing our strategy for regulatory clearance in the US, while focusing on commercial rollout in a variety of overseas markets.” 

Recently, Nexalin revealed positive data from a clinical trial that assessed its neurostimulation device in veteran patients with combat-related mild traumatic brain injury.